StockData

BioCryst Pharmaceuticals vs Travere Therapeutics

BCRX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and TVTX compare

Travere Therapeutics is the larger company, worth 2.5 times as much as BioCryst Pharmaceuticals ($4.8B against $1.9B).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 68.7% for BioCryst Pharmaceuticals).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −40.9% at BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXTVTX
Size and price
Market cap$1.9B$4.8B
Share price$7.50$51.10
Change, 1 year5.9%48.1%
Change, 5 years−39.9%76.0%
Beta (5Y)0.581.91
Employees435497
StockData Score
Total score9 (better)6
Valuation score1 (better)0
Growth score4 (better)3
Performance score22
Health score2 (better)1
Dividend score00
Valuation
P/S2.0× (better)8.1×
P/B–196×
EV/EBITDA–197×
P/FCF5.1×–
FCF yield19.5%–
Fair value–$6.01
Margin of safety–−751%
Growth
Revenue growth (TTM)68.7%77.1% (better)
Revenue growth, 5Y average118% (better)19.9%
Profitability
Gross margin97.8%98.6% (better)
Operating margin−33.3%−6.8% (better)
Net margin−40.9%−7.4% (better)
FCF margin39.7%–
Return on equity–−152%
Financial health
Interest coverage−4.2× (better)−4.3×
Current ratio2.324.05 (better)
Altman Z-score−3.832.29 (better)
Piotroski F-score77
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%112%
Held by insiders1.9%1.6%
Insider net buying, 12 months−$4.1M (better)−$110M
Short interest, % of float11.0%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.